GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Clinical trials for GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION trials appear
Sign up with your email to follow new studies for GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Electric eye therapy could slow blinding disease
Disease control Recruiting nowThis study tests if a mild electrical current applied to the eye (transcorneal electrical stimulation) can safely slow the progression of geographic atrophy, a leading cause of blindness in older adults. 70 participants will use a device at home for 30 minutes each week over a ye…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: NA • Sponsor: Okuvision GmbH • Aim: Disease control
Last updated May 26, 2026 11:51 UTC
-
New drug trial aims to slow vision loss from 'Dry' macular degeneration
Disease control Recruiting nowThis study tests a new drug called FWY003 in people with geographic atrophy, an advanced form of age-related macular degeneration that causes blind spots. The goal is to see if different doses can slow the growth of damaged areas in the eye. About 272 adults aged 50 and older wil…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 11:50 UTC
-
New injection aims to slow vision loss from dry AMD
Disease control Recruiting nowThis study tests a single injection of CTx001 into the eye for people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes blind spots. The goal is to see if it is safe and can slow vision loss. About 75 participants will be followed for u…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE1, PHASE2 • Sponsor: Complement Therapeutics • Aim: Disease control
Last updated May 26, 2026 11:48 UTC
-
New combo therapy aims to slow vision loss from dry AMD
Disease control Recruiting nowThis study tests whether adding APL 3007 to the existing drug Syfovre can better slow the progression of geographic atrophy, a form of advanced dry age-related macular degeneration that causes blind spots. About 240 adults aged 60 and older with the condition will receive either …
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 11:45 UTC
-
New shot aims to save sight in dry macular degeneration
Disease control Recruiting nowThis study tests an experimental drug called ADX-038 in 240 people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes blind spots. Participants receive either the drug or a placebo as a shot under the skin. The goal is to see if the drug…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
Gene therapy injection aims to slow vision loss from dry AMD
Disease control Recruiting nowThis study tests a new gene therapy (VV-14295) given as an injection into the eye for people with geographic atrophy, a form of advanced dry age-related macular degeneration that causes blind spots. The goal is to see if it is safe and can slow the growth of these spots. About 62…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE1, PHASE2 • Sponsor: Kriya Therapeutics, Inc. • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
Could a tiny zap save your sight? new trial for dry AMD
Disease control Recruiting nowThis study tests a device that delivers tiny electrical pulses through the eyelid to treat dry age-related macular degeneration (AMD), a leading cause of vision loss. About 100 people with intermediate to advanced dry AMD will receive either real or sham (inactive) treatments ove…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: NA • Sponsor: i-Lumen Scientific AUS PTY LTD • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
New study tracks eye disease progression to uncover clues for future treatments
Knowledge-focused Recruiting nowThis study observes 75 adults aged 55 and older with geographic atrophy (a late stage of age-related macular degeneration) to measure how the condition progresses over a short period. Researchers will use eye exams and imaging to track changes and explore links to genetics and li…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Sponsor: Complement Therapeutics • Aim: Knowledge-focused
Last updated May 26, 2026 11:31 UTC